CLGN (CollPlant Biotechnologies) Gross Margin

CollPlant Biotechnologies (CLGN) is a leading player in regenerative medicine, producing human-identical collagen. The change in gross profit margin reflects cost efficiency dynamics, where the current metric is -587.70. The company supplies rhCollagen for 3D bioprinting and aesthetics using tobacco plants. Business success is based on partnerships with pharmaceutical behemoths and strict control of R&D expenses.
Financial and market metric breakdowns for CollPlant (CLGN)

For CollPlant Biotechnologies (CLGN), which monetizes tobacco-derived collagen synthesis within the regenerative medicine segment, production efficiency determines market value. This gross profit margin chart allows for a real-time assessment of the revenue share net of direct costs, where any deviations signal rising cost of goods sold or a shift in market conditions, helping investors reallocate capital into defensive assets in a timely manner.